Abstract
One hundred forty-four patients with non-small cell lung cancer, the majority (72%) of whom had received previous chemotherapy, were evaluable in this randomized phase II study of N-methylformamide (N-MF), spirogermanium, and 4-demethoxydaunorubicin. There were two partial responses, one each with spirogermanium and 4-demethoxydaunorubicin. There were eight life-threatening complications (mostly hematologic) and two lethal complications (N-MF, hematologic; 4-demethoxydaunorubicin, gastrointestinal). The overall survival ranged from 9 days to 533 days with a median of 17.6 weeks. The following factors were associated with poor survival: Poor initial performance status, prior weight loss, presence of liver or subcutaneous metastases.
Publication types
-
Clinical Trial
-
Randomized Controlled Trial
-
Research Support, U.S. Gov't, P.H.S.
MeSH terms
-
Aged
-
Antineoplastic Agents / adverse effects
-
Antineoplastic Agents / therapeutic use*
-
Carcinoma, Non-Small-Cell Lung / drug therapy*
-
Drug Evaluation
-
Female
-
Formamides / adverse effects
-
Formamides / therapeutic use*
-
Germanium / adverse effects
-
Germanium / therapeutic use*
-
Humans
-
Idarubicin / therapeutic use*
-
Lung Neoplasms / drug therapy*
-
Male
-
Middle Aged
-
Organometallic Compounds / adverse effects
-
Organometallic Compounds / therapeutic use*
-
Prognosis
-
Random Allocation
-
Remission Induction
-
Spiro Compounds / adverse effects
-
Spiro Compounds / therapeutic use*
Substances
-
Antineoplastic Agents
-
Formamides
-
Organometallic Compounds
-
Spiro Compounds
-
Germanium
-
spirogermanium
-
methylformamide
-
Idarubicin